N@N

David Lebovitz Maintained (ALNY) at Buy with Increased Target to $199 on, Jul 15th, 2020

David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Increased Target from $162 to $199 on, Jul 15th, 2020.

David has made no other calls on ALNY in the last 4 months.

There are 8 other peers that have a rating on ALNY. Out of the 8 peers that are also analyzing ALNY, 3 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Esther Rajavelu of "UBS" Maintained at Hold with Increased Target to $122 on, Thursday, May 28th, 2020
• Luca Issi of "RBC Capital" Initiated at Hold and Held Target at $150 on, Wednesday, May 13th, 2020
• Anupam Rama of "JP Morgan" Downgraded from Buy to Hold and Increased Target to $137 on, Thursday, May 7th, 2020

These are the ratings of the 5 analyists that currently disagree with David

---

• Gena Wang of "Barclays" Maintained at Buy with Increased Target to $156 on, Thursday, May 7th, 2020
• Leland Gershell of "Oppenheimer" Maintained at Buy with Increased Target to $162 on, Thursday, May 7th, 2020
• Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $171 on, Thursday, May 7th, 2020
• Alan Carr of "Needham" Maintained at Strong Buy with Increased Target to $160 on, Wednesday, May 6th, 2020
• Christopher Marai of "Nomura" Maintained at Sell and Held Target at $74 on, Tuesday, April 14th, 2020

Contributing Sources

---